FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes

ROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that detailed findings from the Harmony 6 Phase 3 study comparing albiglutide to prandial insulin (Lispro), were presented today at the American Diabetes Association Meeting (ADA) in Philadelphia, USA, and show that the effect is maintained out to 52 weeks. Results from the Harmony 7 Phase 3 study comparing albiglutide (50 mg) to once-daily liraglutide (1.8 mg) were also presented.